secwatch.observer — SEC 8-K summary
======================================

Issuer:     X4 Pharmaceuticals, Inc (XFOR)
CIK:        0001501697
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001628280-24-018773
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

X4 Pharma receives FDA approval for XOLREMDI (mavorixafor), first drug for WHIM syndrome
--------------------------------------------------------------------------------

- XOLREMDI approved for patients 12+ with WHIM syndrome to increase circulating neutrophils and lymphocytes.
- Phase 3 4WHIM trial met primary endpoint (TAT-ANC) vs. placebo (p<0.0001).
- XOLREMDI showed 60% reduction in annualized infection rate vs. placebo.
- X4 granted Rare Pediatric Disease Priority Review Voucher concurrent with approval.
- U.S. commercial launch via specialty pharmacy PANTHERx Rare; X4Connect patient support launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024018773/0001628280-24-018773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501697/000162828024018773/xfor-20240429.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-018773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer